Jennie Hocking MPAS , John B. Eisenga MD , Austin Kluis MD , Kyle A. McCullough MD , Ghadi Moubarak MD , J. Michael DiMaio MD , William Ryan MD
{"title":"Predictors of Survival After Triple Valve Surgery: A Single Center Analysis","authors":"Jennie Hocking MPAS , John B. Eisenga MD , Austin Kluis MD , Kyle A. McCullough MD , Ghadi Moubarak MD , J. Michael DiMaio MD , William Ryan MD","doi":"10.1016/j.atssr.2024.07.021","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Triple valve surgery is a complex operation with high perioperative mortality. Limited data exist regarding the predictors of success associated with this surgery. We report our experience.</div></div><div><h3>Methods</h3><div>A total of 211 sequential patients underwent triple valve surgery at 1 hospital from November 2007 through July 2022. Baseline characteristics, operative details, and mortality outcomes were reviewed.</div></div><div><h3>Results</h3><div>Eighty-two (38.9%) were redo operations and 68 (32.2%) were urgent. Commonly, aortic (n = 194; 91.4%) and mitral (n = 140; 66.4%) valves were replaced, and the tricuspid valve (n = 189; 89.6%) repaired. Concomitant procedures were done in 28% of patients. Thirty-day mortality was 21 of 211 (9.95%). Kaplan-Meyer survival at 1 and 7 years was 86.0% (interquartile range, 79%-93%) and 64.0% (interquartile range, 55%-74%), respectively. On multivariate regression, end-stage renal disease (hazard ratio, 4.16; <em>P</em> = .003) was associated with mortality, and mitral valve replacement (hazard ratio, 0.44; <em>P</em> = .009) was associated with improved long-term survival.</div></div><div><h3>Conclusions</h3><div>Despite the high number of redo and concomitant procedures, we report a 30-day mortality rate under 10% and an 86% 1-year survival. In our series, mitral valve replacement conferred a long-term survival benefit.</div></div>","PeriodicalId":72234,"journal":{"name":"Annals of thoracic surgery short reports","volume":"3 1","pages":"Pages 25-30"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of thoracic surgery short reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772993124003346","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Triple valve surgery is a complex operation with high perioperative mortality. Limited data exist regarding the predictors of success associated with this surgery. We report our experience.
Methods
A total of 211 sequential patients underwent triple valve surgery at 1 hospital from November 2007 through July 2022. Baseline characteristics, operative details, and mortality outcomes were reviewed.
Results
Eighty-two (38.9%) were redo operations and 68 (32.2%) were urgent. Commonly, aortic (n = 194; 91.4%) and mitral (n = 140; 66.4%) valves were replaced, and the tricuspid valve (n = 189; 89.6%) repaired. Concomitant procedures were done in 28% of patients. Thirty-day mortality was 21 of 211 (9.95%). Kaplan-Meyer survival at 1 and 7 years was 86.0% (interquartile range, 79%-93%) and 64.0% (interquartile range, 55%-74%), respectively. On multivariate regression, end-stage renal disease (hazard ratio, 4.16; P = .003) was associated with mortality, and mitral valve replacement (hazard ratio, 0.44; P = .009) was associated with improved long-term survival.
Conclusions
Despite the high number of redo and concomitant procedures, we report a 30-day mortality rate under 10% and an 86% 1-year survival. In our series, mitral valve replacement conferred a long-term survival benefit.